Vicero Bio

Executive Summary

Vicero Bio is a San Diego-based preclinical biotechnology company founded in 2021, dedicated to advancing a novel class of multi-specific cancer therapies termed VINCOBODIES. Built on VHH (nanobody) technology, VINCOBODIES are designed to address critical unmet needs in immunotherapy by enabling safer and smarter combination therapies. The company's platform aims to overcome limitations of conventional antibodies, such as poor tumor penetration and off-target toxicity, through multi-specific targeting that engages multiple immune mechanisms simultaneously. Vicero Bio's approach has the potential to improve efficacy while reducing side effects, positioning it as a next-generation immunotherapy player. As a private, early-stage company, Vicero Bio is currently in the preclinical phase, focusing on target validation and lead optimization across multiple oncology indications. While financial details and specific pipeline candidates are not publicly disclosed, the company's innovative platform and experienced leadership in San Diego's biotech hub suggest a strong foundation for future growth. The success of Vicero Bio hinges on generating compelling preclinical data, securing partnerships or funding, and advancing toward clinical trials.

Upcoming Catalysts (preview)

• Q4 2026Preclinical proof-of-concept data for lead VINCOBODY candidate50% success
• H1 2027Series A financing round60% success
• Q2 2027IND-enabling studies initiation40% success